Physician profile
Jan C Lenz
NPI 1215040944
$665.14
in general payments reported to CMS, 2019-2025
10 companies · $30.97 in 2025
The $30.97 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.43 · 2020: $17.73 · 2021: $165 · 2022: $102 · 2023: $102 · 2024: $149 · 2025: $30.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $159.36 | 2022-2025 | Rocklatan, Clareon |
| Glaukos Corporation | $111.17 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $86.52 | 2019-2021 | |
| Oyster Point Pharma, INC. | $74.37 | 2023-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $66.25 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.86 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $38.65 | 2019-2020 | |
| Alcon Research LLC | $25.77 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $22.18 | 2024 | Xdemvy |
| Thea Pharma INC. | $19.01 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Lenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.